FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					
nours per respon-	se 0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Ty	pe Response	es)															
Name and Address of Reporting Person * Young Richard A				2. Issuer Name and Ticker or Trading Symbol Syros Pharmaceuticals, Inc. [SYRS]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
	OS PHAR	(First) MACEUTIO E, SUITE 3	(Middle) CALS, INC., 620	3. Date of Earliest Transaction (Month/Day/Year) 08/14/2017						r (give title belo	w)	Other (specify b	elow)				
CAMBR	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year) AMBRIDGE, MA 02139 4. If Amendment, Date Original Filed(Month/Day/Year) Solution of the Company of the Co					rting Person		ole Line)									
(City		(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year)	ar) any (Instr. 8) (D) Re		Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)				7. Nature of Indirect Beneficial Ownership (Instr. 4)							
					Code	v	Amour	(A) or (D)	Price			(I) (Instr. 4)					
Common	Stock		08/14/2017		S ⁽¹⁾		3,282	D	\$ 22	420,101			D				
indirectly.	Report on a	separate line to		Derivative Securit	ies Acquire	Pers cont the f	ons whained i	n this for splays a of, or Ben	m are curre	e not req ntly valid	uired to re d OMB cor	nformation espond un ntrol numb	less	CC 1474 (9- 02)			
	1	1	,	e.g., puts, calls, w		1											
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/	Execution Da Year) any	4. Transaction Code Year) (Instr. 8)	of	and Expiration Date (Month/Day/Year) les les led		and Expiration		and Expiration Date		Ame Und Sect	itle and ount of lerlying urities tr. 3 and		9. Number Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersl Form of Derivati Security Direct (I or Indire)
					7, and 3)				_								

Reporting Owners

Powerfun Comment / Address		Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Young Richard A C/O SYROS PHARMACEUTICALS, INC. 620 MEMORIAL DRIVE, SUITE 300 CAMBRIDGE, MA 02139	Х						

Signatures

/s/ Kyle D. Kuvalanka, as attorney-in-fact	08/16/2017
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

